H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc
as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target.
- While the company stated the possibility exists that its COVID-19 antibody, REGEN-COV, may lose its potency against the omicron strain, there is limited knowledge about the latest in a series of variants that naturally arise in the environment, analyst Michael King says.
- Regeneron has already been studying other antibodies, and there are small molecule and other antibody preparations available, says the analyst.
- According to Michael, it is too early to determine what negative effect, if any, there will be on sales of the drug.
- Earlier today, Regeneron's COVID-19 antibody drug could be less effective against Omicron, it said.
- Based on its study of Omicron's individual mutations, "there may be reduced neutralization activity of both vaccine-induced, and monoclonal antibody conveyed immunity," Regeneron said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.